521 MARA Ratings, listed automatically — this index updates itself when a rating publishes.
A
- Abaloparatide for treating osteoporosis after menopause as of August 2024
- Abelacimab for thrombosis (e.g. atrial fibrillation-related stroke prevention and venous thromboembolism) as of January 2026
- Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence as of July 2022
- Abemaciclib for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy as of September 2021
- Abiraterone / zytiga for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer as of August 2021
- Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer as of November 2025
- Acalabrutinib for treating chronic lymphocytic leukaemia as of April 2021
- Adcetris / brentuximab vedotin for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma as of May 2025
- Adquey / difamilast for mild-to-Moderate Atopic Dermatitis in US, EU5, and Japan as of February 2026
- Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy as of August 2025
- Aimovig / erenumab for preventing migraine as of March 2021
- Alecensa / alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer as of November 2024
- Alpelisib / piqray for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer as of August 2022
- Ameluz / Aminolevulinic acid hydrochloride for Superficial Basal Cell Carcinoma Treated with Red-Light Photodynamic Therapy as of October 2026
- Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours as of January 2025
- Anitocabtagene autoleucel for relapsed or refractory multiple myeloma as of April 2026
- Apalutamide / erleada for treating high-risk hormone-relapsed nonmetastatic prostate cancer as of October 2021
- Apixaban / eliquis for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation as of July 2021
- Aqneursa / Levacetylleucine for Ataxia in Patients with Ataxia-Telangiectasia as of October 2026
- Aspaveli / pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria as of March 2022
- Asundexian for secondary prevention after non-cardioembolic ischemic stroke or high-risk transient ischemic attack as of February 2026
- Atebrioz / Zilurgisertib for Fibrodysplasia Ossificans Progressiva as of October 2026
- Atezolizumab / tecentriq for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable as of October 2021
- Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer as of September 2022
- Atezolizumab for untreated metastatic non-small-cell lung cancer (NSCLC) as of June 2021
- Atogepant for preventing migraine as of May 2024
- Avapritinib for treating advanced systemic mastocytosis as of November 2024
- Avatrombopag for treating primary chronic immune thrombocytopenia as of December 2022
- Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy as of May 2022
- Avelumab for treating metastatic Merkel cell carcinoma as of April 2021
- Avelumab for untreated metastatic Merkel cell carcinoma as of April 2021
- Avlayah / tividenofusp alfa-eknm for in treating neurologic manifestations of Hunter syndrome as of April 2026
- Avutometinib plus dafacitinib for kRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer as of February 2026
- Avutometinib plus defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer as of October 2026
B
- Baricitinib for treating moderate to severe atopic dermatitis as of March 2021
- Baxdrostat for treating uncontrolled and resistant hypertension as of September 2025
- Baxdrostat for treatment-Resistant Hypertension as of April 2026
- Baxfendy / baxdrostat for treating uncontrolled or resistant hypertension as of June 2026
- Belumosudil for chronic Graft-Versus-Host Disease After Failure of Prior Systemic Therapy as of June 2026
- Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over as of February 2024
- Benlysta / belimumab for treating active autoantibody-positive systemic lupus erythematosus as of December 2021
- Bevacizumab gamma / lytenava for treating wet age-related macular degeneration as of December 2024
- Bimzelx / bimekizumab for treating active psoriatic arthritis as of October 2023
- Bimzelx / bimekizumab for treating axial spondyloarthritis as of October 2023
- Bimzelx / bimekizumab for treating moderate to severe plaque psoriasis as of September 2021
- Bivigam for primary humoral immunodeficiency as of August 2025
- Blinatumomab for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia as of March 2025
- Blujepa / gepotidacin for treating uncomplicated urinary tract infections as of February 2026
- Brensocatib for treating non-cystic fibrosis bronchiectasis as of August 2025
- Brepocitinib / pf-06700841 for dermatomyositis as of April 2026
- Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over as of June 2023
- Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma as of February 2021
- Brigatinib / alunbrig for treating ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor as of January 2021
- Brolucizumab / beovu for treating visual impairment due to diabetic macular oedema as of August 2022
- Brolucizumab / beovu for treating wet age-related macular degeneration as of February 2021
- Brukinsa / zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment as of September 2024
- Brukinsa / zanubrutinib for treating Waldenstrom’s macroglobulinaemia as of October 2022
- Bulevirtide for treating chronic hepatitis D as of June 2023
- Bysanti / milsaperidone for in the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder as of May 2026
C
- Cabometyx / cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine as of November 2023
- Cabometyx / cabozantinib for treating advanced hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib as of December 2022
- Cabotegravir / rilpivirine for treating HIV-1 infection as of January 2022
- Cabotegravir for preventing HIV-1 in adults and young people as of November 2025
- Cabozantinib / nivolumab for untreated advanced renal cell carcinoma as of April 2024
- Cagrilintide and semaglutide (cagrisema) for treating Obesity and Overweight With Obesity-Related Comorbidities as of February 2026
- Cagrilintide-semaglutide for treating obesity with or without type 2 diabetes as of July 2025
- Camizestrant / azd9833 for hR-positive, HER2-negative advanced breast cancer as of April 2026
- Camizestrant for eR-Positive HER2-Negative Advanced Breast Cancer as of June 2026
- Capivasertib for PTEN-deficient metastatic androgen pathway modulation-naive or -sensitive prostate cancer as of August 2026
- Capivasertib for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment as of May 2025
- Caplyta / lumateperone for treating schizophrenia as of January 2026
- Cd388 for prophylaxis against influenza as of January 2026
- Cemiplimab / libtayo for untreated advanced non-small-cell lung cancer as of November 2025
- Cemiplimab for treating advanced cutaneous squamous cell carcinoma as of June 2022
- Cenobamate / ontozry for treating focal onset seizures in epilepsy as of May 2025
- Cenobamate for treating focal onset seizures in epilepsy as of July 2025
- Centanafadine for Adult ADHD as of August 2026
- Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma as of August 2021
- Cipaglucosidase alfa / pombiliti for treating late-onset Pompe disease as of August 2023
- Cosibelimab / UNLOXYT for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma as of August 2026
- Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer as of December 2024
- Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over as of November 2024
- Crysvita / burosumab for treating X-linked hypophosphataemia in adults as of August 2024
D
- Dabrafenib / trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer as of June 2023
- Dabrafenib / trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over as of May 2024
- Danicopan for treating paroxysmal nocturnal haemoglobinuria as of October 2024
- Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction as of June 2023
- Darolutamide for treating hormone-sensitive metastatic prostate cancer as of June 2023 – Market Access Risk Assessment
- Darolutamide for treating hormone-sensitive metastatic prostate cancer as of November 2025
- Darzalex / daratumumab for treating multiple myeloma in adults who have had just 1 previous line of treatment as of June 2023
- Darzalex / daratumumab for treating newly diagnosed systemic amyloid light-chain amyloidosis as of March 2024
- Darzalex / daratumumab for treating relapsed and refractory multiple myeloma as of April 2022
- Darzalex / daratumumab for untreated multiple myeloma when a stem cell transplant is suitable as of February 2022
- Darzalex / daratumumab for untreated multiple myeloma when a stem cell transplant is unsuitable as of October 2023
- Datopotamab deruxtecan for the treatment of HR-positive, HER2-negative metastatic breast cancer as of August 2025
- Dawnzera / donidalorsen for prevention of Hereditary Angioedema Attacks as of February 2026
- Daybue / Trofinetide for Rett Syndrome as of October 2026
- Delgocitinib for treating moderate to severe chronic hand eczema as of November 2025
- Denecimig / Frehemgo for Prophylaxis of Bleeding Episodes in Haemophilia A as of October 2026
- Deucravacitinib for treating moderate to severe plaque psoriasis as of June 2023
- Deucrictibant for on-Demand Treatment of HAE Attacks as of September 2025
- Deucrictibant for prophylaxis for hereditary angioedema as of June 2025
- Difelikefalin for treating pruritus in people having haemodialysis as of May 2023
- Diroximel fumarate for treating relapsing-remitting multiple sclerosis as of June 2022
- Donanemab for slowing cognitive decline in early Alzheimer’s disease as of August 2025
- Dostarlimab / jemperli for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency as of March 2022
- Dostarlimab / jemperli for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency as of May 2025
- Dostarlimab for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency as of December 2025
- Doxecitine plus doxribtimine (kygevvi) for tK2 Deficiency as of February 2026
- Dupixent / dupilumab for treating moderate to severe prurigo nodularis as of March 2024
- Dupixent / dupilumab for treating severe asthma with type 2 inflammation as of December 2021
- Durvalumab / imfinzi for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation as of June 2022
- Durvalumab / imfinzi for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy as of October 2025
- Durvalumab / tremelimumab for untreated advanced or unresectable hepatocellular carcinoma as of August 2025
- Durvalumab for treating resectable non-small-cell lung cancer as of January 2025
- Durvalumab for treating unresectable or advanced biliary tract cancer as of January 2024
- Durvalumab for untreated extensive-stage small-cell lung cancer as of February 2025
E
- Edoxaban / lixiana for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation as of July 2021
- Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over as of April 2025
- Ekterly / sebetralstat for treating Acute Attacks of Hereditary Angioedema as of February 2026
- Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment as of February 2025
- Elevidys / delandistrogene moxeparvovec for duchenne muscular dystrophy (DMD) as of January 2026
- Elexacaftor for treating cystic fibrosis as of August 2025
- Elrexfio / elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments as of December 2024
- Emcitate / Tiratricol for Peripheral Thyrotoxicosis in MCT8 Deficiency as of October 2026
- Empagliflozin / jardiance for treating chronic heart failure with reduced ejection fraction as of March 2022
- Emrelis / telisotuzumab vedotin-tllv for previously Treated High c-Met Overexpressing Non-Squamous NSCLC as of February 2026
- Encorafenib plus cetuximab for treating BRAF V600E mutation-positive metastatic colorectal cancer as of January 2021
- Enflonsia / clesrovimab-cfor for prevention of RSV Lower Respiratory Tract Disease in Neonates and Infants as of February 2026
- Enfortumab vedotin / padcev for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable as of September 2025
- Enhertu / trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments as of February 2023
- Enhertu / trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies as of May 2021
- ENSACOVE / Ensartinib for ALK-Positive Advanced NSCLC as of August 2026
- Entrectinib for treating NTRK fusion-positive solid tumours as of August 2020 – Market Access Risk Assessment
- Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer as of August 2020 – Market Access Risk Assessment
- Enzalutamide / xtandi for treating hormone-sensitive metastatic prostate cancer as of July 2021
- Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments as of March 2024
- Epidyolex for treating seizures caused by tuberous sclerosis complex as of March 2023
- Eplontersen for treating hereditary transthyretin-related amyloidosis as of November 2024
- Eptinezumab / vyepti for preventing migraine as of March 2023
- Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor as of May 2025
- Erleada / apalutamide for treating hormone-sensitive metastatic prostate cancer as of October 2021
- Etcamah / Camizestrant for Locally Advanced or Metastatic ER-Positive/HER2-Negative Breast Cancer as of August 2026
- Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B as of July 2024
- Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over as of March 2024
- Etripamil for acute PSVT episode termination as of February 2026
- Evkeeza / evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over as of September 2024
- Evrysdi / risdiplam for treating spinal muscular atrophy as of December 2023
- Evusheld / tixagevimab plus cilgavimab for preventing COVID-19 as of June 2023
- Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over as of February 2025
- Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over as of September 2024
- Exdensur / depemokimab for treating Severe Eosinophilic Asthma as of February 2026
F
- Farabursen for Autosomal Dominant Polycystic Kidney Disease as of September 2026
- Faricimab / vabysmo for treating diabetic macular oedema as of June 2022
- Faricimab / vabysmo for treating wet age-related macular degeneration as of June 2022
- Fasenra / benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis as of September 2025
- Fayuvi / Rebisufligene etisparvovec for mucopolysaccharidosis type IIIA as of October 2026
- Fedratinib / inrebic for treating disease-related splenomegaly or symptoms in myelofibrosis as of November 2024
- Felzartamab for treating Antibody_Mediated Rejection in Kidney Transplant Patients as of April 2026
- Filgotinib for treating moderate to severe rheumatoid arthritis as of February 2021
- Filgotinib for treating moderately to severely active ulcerative colitis as of June 2022
- Finerenone / kerendia for treating chronic kidney disease in type 2 diabetes as of March 2023
- Fintepla / fenfluramine for treating seizures associated with Dravet syndrome as of July 2022
- Fintepla / fenfluramine for treating seizures associated with Lennox-Gastaut syndrome in people 2 years and over as of March 2025
- Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema as of March 2024
- Forxiga / dapagliflozin for treating chronic heart failure with reduced ejection fraction as of February 2021
- Forxiga / dapagliflozin for treating chronic kidney disease (CKD) as of March 2022
- Forzinity / elamipretide for barth Syndrome as of February 2026
- Foslevodopa-foscarbidopa for treating advanced levodopa-responsive Parkinson’s with motor symptoms as of November 2023
- Fostamatinib for treating refractory chronic immune thrombocytopenia as of October 2022
- Foundayo / orforglipron for managing overweight and obesity as of June 2026
- Fremanezumab for preventing migraine as of February 2022
- Fruquintinib for previously treated metastatic colorectal cancer as of July 2025
- Futibatinib for treating locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement that has progressed after at least one prior line of systemic therapy as of September 2024
- Fylrevy / estetrol for in Hormone Replacement Therapy in Postmenopausal Women as of May 2026
G
- Galcanezumab for preventing migraine as of November 2020 – Market Access Risk Assessment
- Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over as of February 2025
- Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over as of October 2025
- Gavreto / pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer as of August 2022
- Gazyva / Obinutuzumab for Frequently Relapsing or Steroid-Dependent Childhood-Onset Idiopathic Nephrotic Syndrome as of October 2026
- Gilteritinib for treating relapsed or refractory acute myeloid leukaemia as of August 2020 – Market Access Risk Assessment
- Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments as of October 2023
- Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma as of December 2025
- Gomekli / mirdametinib for symptomatic, inoperable plexiform neurofibromas in neurofibromatosis type 1 as of March 2026
- Guselkumab for previously treated moderately to severely active Crohn’s disease as of August 2025
- Guselkumab for treating moderately to severely active ulcerative colitis as of August 2025
H
- Hepcludex / bulevirtide for chronic Hepatitis Delta in Adults Without Cirrhosis or With Compensated Cirrhosis as of June 2026
- Hernexeos / zongertinib for previously Treated HER2-Mutant NSCLC as of February 2026
- Hovilpri / Pritelivir for Herpes Simplex Virus Mucocutaneous Lesions in Immunocompromised Adults as of October 2026
- Hyrnuo / Sevabertinib for First-Line Locally Advanced or Metastatic Non-Squamous NSCLC with HER2 (ERBB2) Tyrosine Kinase Domain Activating Mutations as of October 2026
I
- Ibrutinib / venetoclax for untreated chronic lymphocytic leukaemia as of May 2023
- Ibtrozi / taletrectinib for locally Advanced or Metastatic ROS1-Positive NSCLC as of February 2026
- Icosapent ethyl for reducing the risk of cardiovascular events in people with raised triglycerides as of July 2022
- ICOTYDE / Icotrokinra for Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents Aged Twelve Years and Older Weighing at Least Forty Kilograms as of August 2026
- Icotyde / icotrokinra for moderate-to-severe plaque psoriasis in patients aged 12+ years and ³40 kg as of April 2026
- Icotyde for treating moderate-to-severe plaque psoriasis in adults and adolescents aged 12+ as of April 2026
- Idefirix / imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease as of July 2022
- Imbruvica / ibrutinib for treating Waldenstrom’s macroglobulinaemia as of June 2022
- Inluriyo / imlunestrant for eSR1-Mutated Advanced or Metastatic Breast Cancer After Endocrine Therapy as of February 2026
- Insulin efsitora alfa for Adults With Type 2 Diabetes as of August 2026
- Iptacopan / fabhalta for treating paroxysmal nocturnal haemoglobinuria as of September 2024
- Iqirvo / elafibranor for treating primary biliary cholangitis in adults as of November 2024
- Isatuximab / sarclisa for untreated multiple myeloma when a stem cell transplant is unsuitable as of September 2025
- Isatuximab for treating relapsed and refractory multiple myeloma as of November 2020 – Market Access Risk Assessment
- Isembyld / Apitegromab-mstn for Spinal Muscular Atrophy: Evidence Assessment for the United States, EU5, and Japan as of October 2026
- Itulazax for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen as of August 2025
- Ivosidenib / tibsovo for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments as of January 2024
- Ivosidenib for untreated acute myeloid leukaemia with an IDH1 R132 mutation as of June 2024
- Ixekizumab / taltz for treating axial spondyloarthritis as of July 2021
J
- Jardiance / empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction as of November 2023
- Jardiance / empagliflozin for treating chronic kidney disease (CKD) as of December 2023
- Jascayd for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis as of June 2026
- Jaypirca / Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Without a Known 17p Deletion as of October 2026
- Jorveza / budesonide for inducing remission of eosinophilic oesophagitis as of June 2021
- Juvmo / Tavapadon for Parkinson’s Disease as of October 2026
K
- Kesimpta / ofatumumab for treating relapsing-remitting multiple sclerosis as of May 2021
- Keytruda / pembrolizumab for treating persistent, recurrent or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ³ 1 as of December 2023
- Keytruda / pembrolizumab for untreated locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express PD-L1 with a CPS of 10 or more as of August 2024
- Kimmtrak / tebentafusp for treating advanced uveal melanoma as of January 2025
- Kineret / anakinra for treating Still’s disease as of March 2021
- Kinpeygo / budesonide for treating primary IgA nephropathy as of October 2025
- Kisqali / ribociclib for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence as of August 2025
- Kisqali / ribociclib for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy as of March 2021
- Klygefa / Gefurulimab for Generalised Myasthenia Gravis as of October 2026
- Kuvan / sapropterin for treating hyperphenylalaninaemia in phenylketonuria as of September 2021
- Kymriah / tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under as of May 2024
- Kyprolis / carfilzomib for treating multiple myeloma in adults who have had only 1 previous therapy, which included bortezomib as of April 2021
L
- Lagevrio / molnupiravir for treating COVID-19 as of April 2025
- Larotrectinib for treating NTRK fusion-positive solid tumours as of May 2020 – Market Access Risk Assessment
- Latanoprost-netarsudil for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension as of October 2024
- Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over as of July 2024
- Lemtrada / alemtuzumab for treating highly active relapsing-remitting multiple sclerosis as of May 2024
- Leniolisib for in Activated Phosphoinositide 3-Kinase Delta Syndrome in Adults and Adolescents Weighing 45 Kilograms or More as of May 2026
- Lenvatinib / pembrolizumab for untreated advanced renal cell carcinoma in adults as of January 2023
- Leqembi / lecanemab for early AlzheimerÕs Disease as of March 2026
- Leqembi / lecanemab for treating early Alzheimer’s disease as of September 2025
- Leqvio / inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia as of October 2021
- Lerochol / lerodalcibep-liga for lDL-C Reduction in adults with hypercholesterolemia, including HeFH as of February 2026
- Lerodalcibep for Hypercholesterolaemia as of August 2026
- Levodopa-carbidopa intestinal gel for in Motor Fluctuations in Advanced Parkinson Disease as of May 2026
- Lifyorli for platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Prior Bevacizumab as of April 2026
- Linvoseltamab-gcpt for relapsed or refractory multiple myeloma after at least four prior lines of therapy as of February 2026
- Linzagolix for treating moderate to severe symptoms of uterine fibroids as of August 2024
- LIPFENDRA / Enlicitide for treating primary hypercholesterolemia or mixed dyslipidemia as of August 2026
- Lisocabtagene maraleucel / breyanzi for treating relapsed or refractory large B-cell lymphoma after 1L chemoimmunotherapy w/ stem cell transplant is suitable as of March 2025
- Lisraya / Brepocitinib for Dermatomyositis as of October 2026
- Litfulo / ritlecitinib for treating severe alopecia areata in people 12 years and over as of March 2024
- Lokelma / sodium zirconium cyclosilicate for treating hyperkalaemia as of January 2022
- Lonvo-z / lonvoguran ziclumeran for prevention of hereditary angioedema attacks as of April 2026
- Lorlatinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) previously not treated with an ALK inhibitor as of July 2023 – Market Access Risk Assessment
- Lorviqua / lorlatinib for aLK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor as of October 2025
- Lumryz for treating cataplexy or excessive daytime sleepiness in narcolepsy as of January 2026
- Lumvoa / Veligrotug for Thyroid Eye Disease as of October 2026
- Lumykras / sotorasib for treating KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer as of March 2022
- Lunsumio / mosunetuzumab for treating relapsed or refractory follicular lymphoma as of May 2023
- Lupkynis / voclosporin for treating lupus nephritis as of May 2023
- Lurbinectedin for in Maintenance Treatment of Extensive-Stage SCLC After First-Line Induction Without Disease Progression as of May 2026
- Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure as of January 2020 – Market Access Risk Assessment
- Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments as of November 2023
- Lynavoy / linerixibat for cholestatic pruritus associated with primary biliary cholangitis as of April 2026
- LYNAVOY / Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis as of August 2026
- Lynkuet / elinzanetant for menopausal Vasomotor Symptoms as of February 2026
- Lynparza / olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy as of March 2024
- Lynparza / olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy as of February 2025
- Lynparza / olaparib for untreated hormone-relapsed metastatic prostate cancer as of February 2024
- Lyrfigtu / Lirafugratinib for Unresectable or Metastatic Cholangiocarcinoma as of October 2026
M
- Maribavir for treating refractory cytomegalovirus infection after transplant as of January 2023
- Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy as of September 2023
- Mavenclad / cladribine for treating active relapsing forms of multiple sclerosis as of April 2025
- Mavenclad / cladribine for treating relapsing-remitting multiple sclerosis as of May 2024
- Mavorixafor for severe chronic neutropenia as of August 2025
- Mezigdomide for Adult Relapsed or Refractory Multiple Myeloma as of August 2026
- Midostaurin / rydapt for treating advanced systemic mastocytosis as of September 2021
- Mimrylo / Rusfertide for Polycythemia Vera as of October 2026
- Minjuvi / tafasitamab for treating relapsed or refractory diffuse large B-cell lymphoma as of May 2023
- Mirikizumab for treating moderately to severely active ulcerative colitis as of October 2023
- Modeyso / dordaviprone for pediatric glioma, specifically H3 K27M-mutant diffuse midline glioma as of January 2026
- Mogamulizumab for previously treated mycosis fungoides and Szary syndrome as of December 2021
- Momelotinib / omjjara for treating myelofibrosis-related splenomegaly or symptoms as of March 2024
- Mounjaro / tirzepatide for managing overweight and obesity as of December 2024
- Mounjaro / tirzepatide for treating type 2 diabetes as of October 2023
- Mounjaro / tirzepatide for treating type 2 diabetes as of September 2025
- Mrna-1083 / mcombriax for in active immunization against influenza disease and COVID-19 in adults aged 50 years and older as of May 2026
N
- Nadofaragene firadenovec for in High-Grade BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer With Carcinoma in Situ as of May 2026
- Namuscla / mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders as of December 2021
- Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis as of May 2024
- Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over as of July 2025
- Nerandomilast for idiopathic Pulmonary Fibrosis as of February 2026
- Nereus / tradipitant for vomiting induced by motion sickness in adults as of February 2026
- Neupogen / filgrastim for the treatment of severe chronic neutropenia as of August 2025
- Nexviadyme / avalglucosidase alfa for treating Pompe disease as of August 2022
- Nezglyal / Leriglitazone for Cerebral Adrenoleukodystrophy as of October 2026
- Nilemdo / bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia as of April 2021
- Ninlaro / ixazomib citrate for treating relapsed or refractory multiple myeloma as of February 2023
- Nipocalimab for generalized myasthenia gravis as of August 2025
- Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy as of February 2021
- Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer as of April 2022
- Nirmatrelvir plus other therapies for treating COVID-19 as of May 2025
- Nivolumab / ipilimumab for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency as of July 2021
- Nivolumab / ipilimumab for untreated advanced renal cell carcinoma as of March 2022
- Nivolumab / ipilimumab for untreated metastatic non-small-cell lung cancer as of September 2021
- Nivolumab / ipilimumab for untreated unresectable malignant pleural mesothelioma as of August 2022
- Nivolumab / ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency as of May 2025
- Nivolumab / opdivo for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease as of March 2021
- Nivolumab / opdivo for adjuvant treatment of invasive urothelial cancer at high risk of recurrence as of August 2022
- Nivolumab / opdivo for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer as of November 2021
- Nivolumab / opdivo for advanced non-squamous non-small-cell lung cancer after chemotherapy as of July 2021
- Nivolumab / opdivo for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy as of October 2021
- Nivolumab / opdivo for treating unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine and platinum-based combination chemotherapy as of June 2021
- Nivolumab / opdivo for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma as of January 2023
- Nivolumab / opdivo for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma as of February 2023
- Nivolumab / relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over as of February 2024
- Nivolumab for neoadjuvant treatment of resectable non-small-cell lung cancer as of March 2023
- Nucala / mepolizumab for treating severe eosinophilic asthma as of February 2021
- Nuzolvence / zoliflodacin for uncomplicated Urogenital Gonorrhea in US, EU5, and Japan as of February 2026
O
- Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia as of December 2025
- Ofev / nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80 % predicted as of February 2023
- Ofev / nintedanib for treating progressive fibrosing interstitial lung diseases as of November 2021
- Ohtuvayre / ensifentrine for maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) as of July 2025
- Olaparib / lynparza for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer as of January 2024
- Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy as of May 2023
- Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy as of July 2023
- Olaparib for treating hormone-relapsed metastatic prostate cancer with BRCA1 or BRCA2 mutations that has progressed after a newer hormonal treatment as of May 2023
- Olumiant / baricitinib for treating severe alopecia areata as of October 2023
- Onureg / azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy as of October 2022
- Orforglipron for obesity and Type 2 Diabetes as of July 2025
- Orladeyo / berotralstat for preventing recurrent attacks of hereditary angioedema as of October 2021
- Orzeyful / Oveporexton for Narcolepsy Type 1 as of August 2026
- Osimertinib / tagrisso for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection as of February 2025
- Osimertinib for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as of May 2025
- OTARMENI / Lunsotogene parvec-cwha for Biallelic OTOF Variant-Associated Hearing Loss as of August 2026
- OTARMENI / Lunsotogene parvec-cwha for biallelic OTOF variant–associated hearing loss as of September 2026
- Ozurdex / dexamethasone for treating diabetic macular oedema as of September 2022
- Ozureprubart for food Allergy as of January 2026
P
- Palbociclib / ibrance for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy as of October 2022
- Palforzia for treating peanut allergy in children and young people as of February 2022
- Paltusotine for maintenance Treatment of Acromegaly in Adults as of June 2026
- Paltusotine for treating adult acromegaly in the US, EU five, and Japan as of February 2026
- Pasatru / Garetosmab for Fibrodysplasia Ossificans Progressiva as of October 2026
- Pegunigalsidase alfa for treating Fabry disease as of October 2023
- Pegzilarginase-nbln for in hyperargininemia in arginase 1 deficiency as of May 2026
- Pemaryze / pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement as of August 2021
- Pembrolizumab / keytruda for adjuvant treatment of completely resected stage 3 melanoma with lymph node involvement as of February 2022
- Pembrolizumab / keytruda for adjuvant treatment of renal cell carcinoma at increased risk of recurrence as of October 2022
- Pembrolizumab / keytruda for adjuvant treatment of resected non-small-cell lung cancer as of February 2025
- Pembrolizumab / keytruda for adjuvant treatment of resected stage 2B or 2C melanoma as of October 2022
- Pembrolizumab / keytruda for neoadjuvant and adjuvant treatment of triplenegative early or locally advanced breast cancer as of December 2022
- Pembrolizumab / keytruda for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency as of September 2023
- Pembrolizumab / keytruda for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS of 1 or more as of June 2024
- Pembrolizumab / keytruda for treating advanced or recurrent endometrial cancer as of June 2023
- Pembrolizumab / keytruda for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy as of April 2021
- Pembrolizumab / keytruda for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies as of February 2022
- Pembrolizumab / keytruda for treating resectable non-small-cell lung cancer as of November 2024
- Pembrolizumab / keytruda for treating triple-negative, locally recurrent unresectable or metastatic breast cancer as of June 2022
- Pembrolizumab / keytruda for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma as of August 2024
- Pembrolizumab / keytruda for untreated metastatic squamous non-small-cell lung cancer as of February 2022
- Pembrolizumab for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults as of August 2025
- Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma as of May 2024
- Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over as of May 2024
- Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency as of June 2021
- Pembrolizumab for untreated, metastatic, non-squamous non-small-cell lung cancer as of March 2021
- Penpulimab-kcqx for recurrent or Metastatic Nasopharyngeal Carcinoma as of February 2026
- Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea as of March 2022
- Pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm as of June 2026
- Polatuzumab vedotin for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL) as of March 2023
- Ponesimod / ponvory for treating relapsing-remitting multiple sclerosis as of February 2022
- Povetacicept (alpn-303) for treatment of primary IgA nephropathy as of April 2026
- Povofortay / Povorcitinib for Moderate-to-Severe Hidradenitis Suppurativa in Adults Refractory or Intolerant to Anti-TNF Therapy as of October 2026
- Pradaxa / dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation as of July 2021
Q
- Qfitlia / fitusiran for preventing bleeding episodes in hemophilia A or B as of February 2026
- Quizartinib / vanflyta for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia as of October 2024
- Quviviq / daridorexant for treating long-term insomnia as of October 2023
R
- Ranibizumab / lucentis for the treatment of age-related macular degeneration as of May 2024
- Ranibizumab / lucentis for treating choroidal neovascularisation associated with pathological myopia as of May 2024
- Ranibizumab / lucentis for treating visual impairment caused by macular oedema secondary to retinal vein occlusion as of May 2024
- Ranibizumab for treating visual impairment due to diabetic macular oedema as of October 2023
- Rasonque / Daraxonrasib for Metastatic Pancreatic Cancer as of October 2026
- Ravulizumab / ultomiris for treating atypical haemolytic uraemic syndrome as of June 2021
- Raxone / idebenone for treating visual impairment in LeberÕs hereditary optic neuropathy in people 12 years and over as of August 2025
- Redemplo / plozasiran for familial Chylomicronemia Syndrome as of February 2026
- Redemplo / plozasiran for treating familial chylomicronemia syndrome as of June 2026
- Relacorilant for in Platinum-Resistant Epithelial Ovarian Cancer as of May 2026
- Relugolix for treating hormone-sensitive prostate cancer as of August 2024
- Remdesivir / veklury for treating COVID-19 as of May 2024
- Remibrutinib for treating chronic spontaneous urticaria after inadequate H1 antihistamine response as of June 2026
- Retatrutide for obesity ± Metabolic Disorders as of July 2025
- Retatrutide for the treatment of obesity as of January 2026
- Retsevmo / selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over as of February 2025
- Retsevmo / selpercatinib for treating RET fusion-positive advanced non-small-cell lung cancer as of February 2025
- Revlimid / lenalidomide for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma as of March 2021
- Revtorpyk / gedatolisib for HR-Positive/HER2-Negative Advanced Breast Cancer as of August 2026
- Rezvilutamide / SHR3680 for Metastatic Prostate Cancer as of August 2026
- Rhapsido / remibrutinib for chronic Spontaneous Urticaria as of February 2026
- Rilzabrutinib for the treatment of immune thrombocytopenia (ITP) as of September 2025
- Rimegepant / vydura for preventing migraine as of July 2023
- Rimegepant / vydura for treating migraine as of October 2023
- Rinvoq / upadacitinib for treating active non-radiographic axial spondyloarthritis as of February 2023
- Rinvoq / upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs as of February 2022
- Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments as of May 2023
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation as of July 2021
- Romosozumab / evenity for treating severe osteoporosis in people after menopause who are at high risk of fracture as of May 2022
- Roxadustat / evrenzo for treating symptomatic anaemia in chronic kidney disease as of July 2022
- Rubraca / rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy as of April 2025
- Rubraca for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer as of September 2024
- Ruxolitinib / opzelura for treating non-segmental vitiligo in people 12 years and over as of August 2025
- Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over as of April 2025
- Ruxolitinib for treating polycythaemia vera as of October 2023
- Rybrevant for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinumbased chemotherapy as of December 2022
- Ryeqo for treating moderate to severe symptoms of uterine fibroids as of October 2022
- Ryeqo for treating symptoms of endometriosis as of April 2025
S
- Scemblix / asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors as of August 2022
- Secukinumab / cosentyx for treating moderate to severe hidradenitis suppurativa as of December 2023
- Secukinumab / cosentyx for treating moderate to severe plaque psoriasis in children and young people as of October 2021
- Secukinumab / cosentyx for treating non-radiographic axial spondyloarthritis as of July 2021
- Selinexor for treating multiple myeloma in adults as of May 2024
- Selinexor for treating relapsed or refractory multiple myeloma after 4 or more treatments as of May 2024
- Selpercatinib / retsevmo for untreated RET fusion-positive advanced non-small-cell lung cancer as of July 2023
- Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over as of February 2025
- Semaglutide for in Non-cirrhotic metabolic dysfunction-associated steatohepatitis with F2-F3 fibrosis as of May 2026
- Senaparib for First-Line Maintenance of Advanced High-Grade Epithelial Ovarian, Fallopian-Tube, or Primary Peritoneal Cancer as of August 2026
- Sepiapterin sephience for treating Hyperphenylalaninemia in Phenylketonuria as of February 2026
- Sevabertinib for treating HER2 Mutant NSCLC as of February 2026
- Sibeprenlimab-szsi / voyxact for reducing proteinuria in adults with primary IgA nephropathy as of February 2026
- Sintilimab for Non-squamous non-small cell lung cancer (adults) as of August 2026
- Skyrizi / risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs as of July 2022
- Skyrizi / risankizumab for treating moderately to severely active Crohn’s disease in people 16 years and over as of May 2023
- Skyrizi / risankizumab for treating moderately to severely active ulcerative colitis as of August 2024
- Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy as of January 2022
- Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea as of March 2022
- Somapacitan for treating growth hormone deficiency in people 3 to 17 years as of June 2025
- Somatrogon for treating growth disturbance in children and young people aged 3 years and over as of February 2023
- Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after prior BTK inhibitor exposure as of June 2026
- Sotatercept for treatment of heart failure with preserved ejection fraction complicated by combined pulmonary hypertension as of November 2025
- Sparsentan for treating primary IgA nephropathy as of October 2025
- Spravato / esketamine for treatment-resistant depression as of December 2022
- Stivarga / regorafenib for previously treated metastatic colorectal cancer as of February 2023
- Survodutide for obesity treatment as of July 2025
- Suzetrigine for treating neuropathic pain as of August 2025
T
- Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments as of December 2025
- Talzenna / talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations as of February 2024
- Targetedrelease for treating primary immunoglobulin A nephropathy as of December 2023 – Market Access Risk Assessment
- Tarlatamab / imdylltra for extensive-stage small-cell lung cancer after 2 or more treatments as of August 2025
- Tarlatamab for relapsed Extensive-Stage Small Cell Lung Cancer After Two or More Prior Lines of Therapy as of June 2026
- Tecentriq / Atezolizumab for Adjuvant Stage III Mismatch Repair–Deficient Colon Cancer with a Fluoropyrimidine and Oxaliplatin as of October 2026
- Teclistamab (tecvayli) for treating relapsed and refractory multiple myeloma after 3 or more treatments as of November 2024
- Tecvayli / teclistamab for treating relapsed/refractory multiple myeloma after 3 or more treatments as of January 2026
- Teduglutide for treating short bowel syndrome as of June 2022
- Tenecteplase for treating acute ischaemic stroke as of July 2024
- Tepmetko / tepotinib for treating advanced non-small-cell lung cancer with METex14 skipping alterations as of May 2022
- Tezspire / tezepelumab for treating severe asthma as of April 2023
- Tirzepatide for managing overweight and obesity as of September 2025
- Tofacitinib / xeljanz for treating active ankylosing spondylitis as of October 2023
- Tofacitinib / xeljanz for treating active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis as of October 2021
- Tolebrutinib for in Adults With Non-Relapsing Secondary Progressive Multiple Sclerosis as of June 2026
- Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis as of August 2025
- Tovorafenib for in Pediatric Low-Grade glioma as of May 2026
- Tozorakimab for COPD as of September 2026
- Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy as of July 2024
- Tregzi for Matched-Donor Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Hematological Malignancies as of October 2026
- Tremfya / guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs as of August 2022
- Treosulfan for preparative conditioning for allogeneic stem cell transplant in AML/MDS as of March 2026
- Trifluridine-tipiracil for treating metastatic gastric cancer or gastrooesophageal junction adenocarcinoma after 2 or more treatments as of December 2022
- Trifluridine-tipiracil plus bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments as of September 2024
- Trodelvy / sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies as of August 2022
- TRUTAKNA / atacicept-vymj for Primary IgA Nephropathy as of August 2026
- Tryngolza / olezarsen for familial Chylomicronemia Syndrome as of June 2026
- Tryngolza / Olezarsen for Severe Hypertriglyceridemia as of August 2026
- Tryptyr / acoltremon for treatment of dry eye disease as of February 2026
- Tucatinib / Tukysa for First-Line Maintenance Treatment of Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer as of October 2026
- Tudriqev / Vusolimogene oderparepvec for Advanced Melanoma as of October 2026
- Tukysa / tucatinib for treating HER2-positive locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies as of April 2022
U
- Ubeslo / Obicetrapib for Primary Hypercholesterolaemia and Mixed Dyslipidaemia as of August 2026
- Ublituximab for treating relapsing forms of multiple sclerosis as of December 2024
- Ultomiris / ravulizumab for treating paroxysmal nocturnal haemoglobinuria as of May 2021
- Upadacitinib / rinvoq for treating active ankylosing spondylitis as of September 2022
- Upadacitinib / rinvoq for treating moderately to severely active Crohn’s disease as of June 2023
- Upadacitinib / rinvoq for treating moderately to severely active ulcerative colitis as of January 2023
- Upadacitinib for treating moderate rheumatoid arthritis as of November 2021
- Utebzi / Tebipenem pivoxil for complicated urinary tract infection, including pyelonephritis as of August 2026
V
- Vabysmo / faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion as of September 2024
- Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease as of January 2025
- Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over as of January 2025
- Vanrafia / atrasentan for reducing proteinuria in primary IgA nephropathy as of February 2026
- Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over as of July 2025
- Venclyxto / venetoclax for treating chronic lymphocytic leukaemia as of June 2022
- Venclyxto / venetoclax for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable as of April 2022
- Venclyxto / venetoclax for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable as of February 2022
- Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment as of June 2026
- Vibegron for treating symptoms of overactive bladder syndrome as of September 2024
- Vimseltinib / romvimza for in symptomatic tenosynovial giant cell tumor as of March 2026
- Vizz / aceclidine for presbyopia as of February 2026
- Vutrisiran / amvuttra for treating hereditary transthyretin-related amyloidosis as of February 2023
- Vutrisiran / amvuttra for treating transthyretin amyloidosis with cardiomyopathy as of December 2025
- Vyndaqel / tafamidis for treating transthyretin amyloidosis with cardiomyopathy as of June 2024
W
- Wegovy / semaglutide for managing overweight and obesity as of September 2023
- Wegovy / semaglutide for weight Management in Adults With Obesity or Overweight and at Least One Weight-Related Comorbidity as of June 2026
- Welireg / Belzutifan for Advanced Clear-Cell Renal Cell Carcinoma After PD-1/PD-L1 Therapy as of October 2026
- Welireg / belzutifan for treating tumours associated with von Hippel-Lindau disease as of October 2024
X
- Xocova / Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 as of August 2026
- Xocova for post-Exposure Prophylaxis of COVID-19 in Adults as of June 2026
- Xolremdi / mavorixafor for wHIM syndrome in patients aged 12 years and older as of May 2026
Y
- Yartemlea / narsoplimab-wuug for treatment of transplant-associated thrombotic microangiopathy as of February 2026
- Yescarta / axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies as of February 2023
- Yescarta / axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy as of June 2023
- Yescarta / axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma after 3 or more systemic treatments as of June 2023
- Yondelis / trabectedin for the treatment of advanced soft tissue sarcoma as of February 2021
- Yuviwel / navepegritide for in Pediatric Achondroplasia With Open Epiphyses as of May 2026
Z
- Zanubrutinib for treating chronic lymphocytic leukaemia as of November 2023
- Zanvastro / zilganersen for Alexander Disease as of October 2026
- Zegfrovy for non-small cell lung cancer with EGFR Exon 20 insertion as of March 2026
- Zenbexus / Iberdomide for Relapsed or Refractory Multiple Myeloma, Second Line or Later, in Combination With Daratumumab and Dexamethasone as of October 2026
- Zeposia / ozanimod for treating moderately to severely active ulcerative colitis as of October 2022
- Zeposia / ozanimod for treating relapsing-remitting multiple sclerosis as of June 2021
- Zeydovio / Glepaglutide for Short Bowel Syndrome in Adults as of October 2026
- Zidesamtinib / Jideytro for Previously Treated ROS1-Positive Metastatic Non-Small Cell Lung Cancer as of October 2026
- Ziftomenib for nPM1-mutant R/R AML as of February 2026
- Ziihera / Zanidatamab for First-Line HER2-Positive Gastroesophageal Adenocarcinoma as of October 2026
- Zolbetuximab for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive as of March 2025
- Zolgensma / onasemnogene abeparvovec for in 5Q Spinal Muscular Atrophy as of May 2026
- Zycubo / copper histidinate for the treatment of Menkes disease as of February 2026
- Zynlonta / loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments as of January 2024